Baker Bros. Advisors’s Sagimet Biosciences SGMT Stock Holding History

Baker Bros. Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.98M	Hold	952,996	–	–	0.03%	76
2025 Q4	$5.64M	Hold	952,996	–	–	0.03%	73
2025 Q3	$6.54M	Hold	952,996	–	–	0.05%	68
2025 Q2	$7.26M	Hold	952,996	–	–	0.07%	59
2025 Q1	$3.11M	Hold	952,996	–	–	0.03%	68
2024 Q4	$4.29M	Sell	952,996 -428,902	-31%	-$2.17M	0.05%	72
2024 Q3	$3.83M	Hold	1,381,898	–	–	0.04%	72
2024 Q2	$4.73M	Hold	1,381,898	–	–	0.06%	67
2024 Q1	$7.49M	Sell	1,381,898 -74,620	-5%	-$536K	0.09%	57
2023 Q4	$7.89M	Buy	1,456,518 +641,159	+79%	+$3.02M	0.09%	53
2023 Q3	$7.18M	Buy	+815,359	New	+$10.9M	0.04%	56

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Baker Bros. Advisors's SGMT Position: Q1 2026 in Review

Baker Bros. Advisors held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 952,996 shares worth $4.98M. The position accounts for 0.03% of the portfolio, ranked #76.

Baker Bros. Advisors first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.89M in Q4 2023. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Baker Bros. Advisors held 952,996 shares of Sagimet Biosciences worth $4.98M as of Q1 2026.
Baker Bros. Advisors left its Sagimet Biosciences share count unchanged in Q1 2026.
Sagimet Biosciences made up 0.03% of Baker Bros. Advisors's portfolio in Q1 2026, its #76 holding.
Baker Bros. Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
Baker Bros. Advisors's Sagimet Biosciences position peaked at $7.89M in Q4 2023.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.